Last updated: April 25, 2026
What are the major supplier categories for phenytoin?
Phenytoin is supplied through three main channels: API manufacturers, formulation/finished-dose manufacturers, and specialty wholesalers/contract packagers that source material globally and provide regulatory-ready supply.
Who supplies phenytoin API (active pharmaceutical ingredient)?
Phenytoin API is manufactured by multiple global suppliers across Europe, India, and China. In practice, buyers typically source from one of two groups: (1) manufacturers with established DMF/CEP support and (2) contract manufacturers that supply compliant lots under quality agreements.
Common phenytoin API supplier footprint (typical global manufacturers):
- Teva API (Teva Global and related API manufacturing entities)
- Aurobindo Pharma
- Sun Pharma / Sun Pharmaceutical Industries
- Hetero Drugs / Hetero Labs
- Zydus (Cadila)
- Cipla (API and manufacturing footprint depending on site allocation)
- Mylan / Viatris legacy sites (where applicable to API sourcing)
- North China-based and Indian specialty API manufacturers (often supply for generics and markets with high price sensitivity)
Who supplies finished-dose phenytoin products (tablets/capsules/injectables)?
Finished-dose brands and generics are produced by global and regional manufacturers. Finished-dose availability varies by country and by whether the market prioritizes brand penetration or generic procurement.
Typical finished-dose supplier categories:
- US/EU generic manufacturers supplying tablets and capsules
- Hospital-focused injectable suppliers supplying phenytoin sodium injection (markets where injectables are still widely used)
- License-based local manufacturers that import bulk API and finish locally to meet national registration rules
What are the most common global sourcing markets for phenytoin?
- United States: procurement tends to prioritize suppliers with established cGMP compliance record and dependable lead times.
- EU/UK: buyers often require CEP alignment or equivalent regulatory dossiers plus QP release workflows.
- India: large-scale generic supply and API capability; frequent use in global tendering.
- China: broad generic API manufacturing capacity with commercial scale.
- MENA and LATAM: frequent reliance on imported API and finished-dose products via established distribution partners.
What documents matter when selecting phenytoin suppliers?
Procurement of phenytoin (API and finished dose) is typically constrained by dossier status and quality system controls. Buyers focus on the following:
- Regulatory dossier support: DMF/ASMF status, CEP (where applicable), and site-specific approvals.
- Quality documentation: CoA batch record traceability, impurity profile alignment, stability protocol.
- Pharmacopeia compliance: USP/EP monographs for phenytoin strength and specification.
- Compatibility and interchangeability: polymorph/form considerations for solid oral dosage; salt form controls for injection (where used).
- Supply continuity terms: minimum batch sizes, fill-rate commitments, and change control clauses.
What is the typical tender/qualification approach for phenytoin procurement?
Most buyers run qualification through:
- Supplier audit readiness (manufacturing quality system and deviation/CAPA track record)
- Product quality fit (impurity acceptance, dissolution specs for oral forms, sterility/pyrogen controls for injectables)
- Commercial reliability (lead times, allocation policy, and logistics coverage)
Supplier map by supply role (actionable procurement lens)
The table below frames where suppliers usually sit in the value chain.
| Supply role |
What the supplier provides |
Buyer use case |
Key qualification gates |
| API manufacturer |
Phenytoin API bulk lots |
Generics, contract manufacturing, compounding support |
DMF/ASMF or CEP, site cGMP, impurity specs |
| Finished-dose manufacturer |
Tablets/capsules/injectables |
Direct-to-market or wholesaler distribution |
Finished product dossier, batch release, stability data |
| Specialty wholesaler / distributor |
Distribution + documentation support |
Supply continuity, tender support, market coverage |
Traceability, temperature/logistics, documentation completeness |
| Contract packager |
Packaging in buyer’s markets |
Local commercialization and registration workflows |
Packaging cGMP, labeling controls, change control |
Key compliance constraints that affect phenytoin sourcing
Phenytoin supply is particularly sensitive to:
- Impurity controls due to narrow therapeutic index considerations in clinical use (procurement specifications usually align to monograph and dossier limits)
- Form-specific controls (salt form and dosage form specifications)
- Batch-to-batch consistency for dissolution and impurity profiles
Key Takeaways
- Phenytoin is typically sourced via API manufacturers and finished-dose manufacturers, with global sourcing concentrated in US/EU market-ready suppliers and high-scale Asian API producers.
- Supplier selection is constrained mainly by regulatory dossier support (DMF/CEP/ASMF), cGMP quality record, impurity specification alignment, and supply continuity terms.
- Procurement effectiveness comes from matching supplier role to need: API for manufacturing, finished dose for distribution, and wholesaler/packager for continuity and local market execution.
FAQs
1) What is the difference between a phenytoin API supplier and a finished-dose manufacturer?
API suppliers provide bulk phenytoin used to manufacture tablets/capsules/injectables; finished-dose manufacturers provide registered drug products ready for distribution.
2) Which regions typically supply phenytoin API at scale?
Indian and Chinese API manufacturing ecosystems dominate volume supply, while US/EU buyers often add regulatory readiness requirements for site acceptance.
3) What documentation do buyers usually require for phenytoin API?
DMF/ASMF or CEP alignment (as applicable), site cGMP evidence, CoA with impurity profile matching, and batch traceability documentation.
4) Is phenytoin supply different for tablets/capsules versus injectables?
Yes. Injectables add sterilization/pyrogen and additional release controls, while oral forms focus heavily on dissolution and solid-state/form consistency.
5) What is the main procurement risk for phenytoin?
Supply continuity tied to manufacturing batch availability, change controls, and regulatory acceptance of quality specifications and dossier updates.
References (APA)
[1] FDA. (n.d.). Drugs@FDA. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
[2] EMA. (n.d.). Human medicines: EPARs and product information. European Medicines Agency. https://www.ema.europa.eu/en/medicines
[3] USP. (n.d.). USP–NF monographs. United States Pharmacopeia. https://www.uspnf.com/
